



**LUPIN**

August 18, 2023

**BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

*Dear Sir/Madam,*

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').**

Vide our letter dated August 24, 2022 (copy enclosed), we had informed the Exchanges regarding the Company having entered into Deed of Assignment with Boehringer Ingelheim International GmbH, Germany, for acquisition of the brands Ondero and Ondero - Met (including trademark rights associated with the brands).

Further to the said disclosure, we are pleased to inform that the Company has completed the acquisition of the said brands.

Enclosed is the Press Release in connection with the above.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS -11973)**

**Encl: - a/a.**



**LUPIN**

August 24, 2022

**BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

*Dear Sir/Madam,*

We are pleased to announce that the Company has entered into Deed of Assignment with Boehringer Ingelheim International GmbH for the acquisition of brands Ondero and Ondero - Met (including trademark rights associated with the brands), which will enable the Company to provide comprehensive and best-in-class treatment options for diabetes management. Particulars are as under: -

**Name of the Acquirer - Lupin Limited**

<b>a)</b>	name of the target entity, details in brief such as size, turnover etc.;	Acquisition of brands 'Ondero' and 'Ondero Met' from Boehringer Ingelheim International GmbH.
<b>b)</b>	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at 'arms-length';	No.
<b>c)</b>	industry to which the entity being acquired belongs;	Pharmaceuticals.
<b>d)</b>	objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The brands relate to medicines for the diabetic segment. Value creation is expected for Lupin's diabetic portfolio.
<b>e)</b>	brief details of any governmental or regulatory approvals required for the acquisition;	No government/regulatory approvals are required.
<b>f)</b>	indicative time period for completion of the acquisition;	August 2023.
<b>g)</b>	nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration.
<b>h)</b>	cost of acquisition of brands;	Euro 26 million.



i)	percentage of shareholding / control acquired and / or number of shares acquired; and	N/A.
j)	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	Boehringer Ingelheim International GmbH is a company incorporated under the laws of Germany. It is engaged in the pharmaceutical industry.

This may kindly be considered as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above is for your information and dissemination.

Thanking you,

**FOR LUPIN LIMITED**

**Rajvardhan Vishnu  
Satam**

Digitally signed by Rajvardhan Vishnu Satam  
DN: cn=Rajvardhan Vishnu Satam,  
2.5.4.20=c19086f961d9f659e973a093a4d3924b2532eb2f496ea7e2abcf74700f5375b7,  
postalCode=400104, street=2404,SEJAL TOWER,SEJAL PARK,LINK ROAD,GOREGAON  
WEST,Mumbai,Melita Nagar,Borivali,Mumbai,Suburban  
pseudoym=0a87cd219ea516a55e4e6851dc3ba5b, title=0191,  
serialNumber=0f8a6e0a08c796663c738ea255af6b475d195f726c067a2ff09c42427  
71b2a, o=Personal, cn=Rajvardhan Vishnu Satam  
Date: 2022.08.24 22:25:35 +05'30'

**R. V. SATAM  
COMPANY SECRETARY  
(ACS -1 1973)**

## Lupin Acquires Brands ONDERO® and ONDERO MET® to expand Diabetes Portfolio in India

**Mumbai, August 18, 2023:** Global pharma major Lupin Limited (Lupin) announced today the acquisition of diabetes brands ONDERO® and ONDERO MET®, from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), including the trademark rights associated with these brands. Lupin has been marketing ONDERO® and ONDERO MET® since 2015 in the Indian market as part of a co-marketing agreement with Boehringer Ingelheim India.

In India, an estimated 77 million people above the age of 18 years have Type-2 Diabetes, while nearly 25 million are pre-diabetic, at higher risk of developing diabetes in the future. ONDERO® (Linagliptin) and ONDERO MET® (Linagliptin + Metformin) are the gold standard in diabetes management. This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes.

“Lupin is at the forefront of providing quality pharmaceutical products to patients. With the acquisition of ONDERO® and ONDERO MET®, we continue to offer a wide portfolio of products to enable access to medication for patients, and further consolidate our position as a market leader in the anti-diabetes segment,” said **Nilesh Gupta, Managing Director, Lupin**.

Commenting on the acquisition, **Rajeev Sibal, President – India Region Formulations, Lupin** said, “The disease burden of diabetes is constantly increasing fueled by the prevalence of obesity and unhealthy lifestyles. This important acquisition reflects our steadfast dedication in empowering healthcare professionals to combat the growing menace of diabetes in India and significantly improve the lives of those facing this challenging disease.”

### About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Follow us on:

Twitter: <https://twitter.com/LupinGlobal>

LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

**For further information or queries, please contact –**

**Shweta Munjal**

Vice President and Head – Corporate Communications & Sustainability

Email: [shwetamunjal@lupin.com](mailto:shwetamunjal@lupin.com)